Thrombocytopenia complications associated with coronary therapeutic drugs: Platelet receptor Glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab

Journal of Invasive Cardiology

Volumn 12, Issue 10, 2000, Pages 528-531

  Coto, Humberto ^a  

^a Adult Cardiology Division   (United States)

Author keywords

Abciximab; Eptifibatide; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; METHODOLOGY; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034295310     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
2. The EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
3. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
4. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
5. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients limited by Unstable Signs and Symptoms (PRISM-PLUS) Study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
6. The IMPACT-II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
7. The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
8. Arjomand H, Magsi ZM, Chang KS, Mascarenhas DA. Abciximab readministration: A single-operator community-hospital experience. Cathet Cardiovasc Intervent 1999;47:294-296.
9. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
10. Elmi F, Oza R, Mascarenhas DAN. Acute profound thrombocytopenia without bleeding complications after abciximab administration. J Invas Cardiol 1999;11:313-315.
11. Fry ETA. Readministration of abciximab in percutaneous coronary intervention. J Invas Cardiol 1999;11:251-258.
12. Joseph T, Marco J, Gregorini L. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Clin Cardiol 1998;21:851-852.
13. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-208.
14. Kereiakes DJ, Essell JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-1163.
15. Tcheng JE, Kereiakes DJ, Braden GA, et al. Readministration of abciximab: Interim report of the ReoPro readministration registry. Am Heart J 1999;138:S33-S38.
16. Bednar B, Bednar RA, Cook JJ, et al. Drug-dependent antibodies against GP IIb/IIIa induced thrombocytopenia (Abstr). Circulation 1996;94(Suppl I):I-99.